產(chǎn)品詳情
簡單介紹：
重組人類Granulocyte-Macrophage集落刺激因子蛋白與其它公司提供的重組蛋白不同，rHuGM-CSF蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人類Granulocyte-Macrophage集落刺激因子蛋白（全長序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測、ELISA等試驗(yàn)中.
詳情介紹：
重組人類Granulocyte-Macrophage集落刺激因子蛋白
| Synonyms | Granulocyte/Macrophage Colony-Stimulating Factor, CSF-2, MGI-1GM, Pluripoietin-α |
| Species | Human |
| Accession | P04141 |
| GeneID | 1437 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人類Granulocyte-Macrophage集落刺激因子蛋白Approximately 14.5 kDa, a single non-glycosylated polypeptide chain containing 127 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | APARSPSPST QPWEHVNAIQ EARRLLNLSR DTAAEMNETV EVISEMFDLQ EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQE |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人類Granulocyte-Macrophage集落刺激因子蛋白Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1.0 EU/μg of rHuGM-CSF as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人類Granulocyte-Macrophage集落刺激因子蛋白 | |
| SDS-PAGE |
|
| Reference |
重組人類Granulocyte-Macrophage集落刺激因子蛋白1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3. 2. 1989. N Engl J Med, 320: 253-4. 3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101. 4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27. 5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31. |
| Background | Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is secreted by a number of different cell types (including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts) in response to cytokine or immune and inflammatory stimulation. It was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors and has functions of stimulates the growth and differentiation of hematopoietic precursor cells from various lineages. GM-CSF has also been reported to have a functional role on non-hematopoietic cells and can induce human endothelial cells to migrate and proliferate. Additionally, it can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. Human GM-CSF shares 54 % sequences identity with mouse GM-CSF, but has no biological effects across species. GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy and has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. |
